title: The end of knight-errantry in GVHD studies.
abstract: In this issue of Blood, Bolaños-Meade et al reported the results of the randomized phase 3 study Blood and Marrow Transplant Clinical Trials Network (BMTCTN) 0802. It compared the addition of mycophenolate mofetil to steroids vs steroids/placebo to treat newly diagnosed acute graft-versus-host disease (GVHD). Unfortunately, it failed to show a significant difference in outcomes.
authors.affiliation: CASE WESTERN RESERVE UNIVERSITY.
authors.forename: Marcos
authors.initials: M
authors.lastname: de Lima
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage*; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D009173:Mycophenolic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives*; D011241:Prednisone / Q000008:administration & dosage*
chemical_list: D000305:Adrenal Cortex Hormones; D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid; D011241:Prednisone